Exelixis Inc (EXEL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $16.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Exelixis Inc (EXEL) P/E Ratio & Valuation History
Exelixis (EXEL) trades at 19.3x trailing earnings and 6.9x sales. Its P/E of 19.3x is above its 5-year median of 18.1x. Its forward P/E is 16.3x. The median P/E across 3 similar companies is 27.7x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 18.4% higher over the next year. Its free cash flow yield is 7.0%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 19.3x |
| Forward P/E | 16.3x |
| Price to sales | 6.9x |
| Price to book | 9.1x |
| EV/EBITDA | 16.5x |
| Price to FCF | 14.4x |
| EV/FCF | 14.1x |
| PEG | 2.3 |
| FCF yield | 7.0% |
Historical Medians
Against its 10-year medians, its P/E is 0.5% above 19.2x, its P/S is 27.8% above 5.4x and its P/B is 122.0% above 4.1x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 19.3x | 18.1x | 19.2x |
| P/S | 6.9x | 4.3x | 5.4x |
| P/B | 9.1x | 3.2x | 4.1x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/E, its P/E ranged from 13.8x in 2018 to 59.6x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $43.83 | 14.2x | 5.2x | 5.7x |
| 2024 | $33.30 | 16.4x | 4.4x | 4.2x |
| 2023 | $23.99 | 26.7x | 4.2x | 3.3x |
| 2022 | $16.04 | 19.6x | 3.2x | 2.1x |
| 2021 | $18.28 | 18.1x | 4.0x | 2.7x |
| 2020 | $20.07 | 32.4x | 6.4x | 3.4x |
| 2019 | $17.62 | 16.2x | 5.6x | 3.3x |
| 2018 | $19.67 | 13.8x | 6.9x | 4.8x |
| 2017 | $30.40 | 59.6x | 20.0x | 33.4x |
| 2016 | $14.91 | N/A | 20.5x | 50.3x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EXEL
What is EXEL's forward P/E ratio?
Exelixis has a forward P/E ratio of 16.3x.
Is EXEL stock overvalued?
GNG's valuation label for EXEL is Fairly valued. Its P/E of 19.3x compares with a median of 27.7x across 3 similar companies.
What is EXEL's price to sales ratio?
Exelixis has a price to sales ratio of 6.9x.
What is Exelixis's average P/E ratio over 5 years?
Exelixis's median P/E over the last 5 years is 18.1x, from 60 month-end values through Oct 2026.
What is EXEL's PEG ratio?
Exelixis has a PEG ratio of 2.3.
EXEL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors